Venatorx Pharmaceuticals is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections.

Defense Threat Reduction Agency (DTRA)

National Institute of Allergy and Infectious Diseases

National Institutes of Health

CARB-X

BioAdvance

Versant Ventures

Abingworth

Foresite Capital

AMR Action Fund

Venatorx Pharmaceuticals, Inc.

Venatorx Pharmaceuticals, Inc., Melinta Therapeutics and MENARINI Group are thrilled to announce positive Phase 3 study results for cUTI in the New England Journal of Medicine: Cefepime-Taniborbactam was superior to meropenem for the primary composite efficacy endpoint and composite efficacy sustained at late follow-up visit  https://bit.ly/49mFrFl

Venatorx is excited to introduce Kirstin H. Lees, MBA
 
Kirstin is joining Venatorx as the Executive Director, Program Management. She will play a significant role in managing and driving our clinical-stage programs at Venatorx.
 
A warm welcome to our newest Venatorx team member, Kirstin!
 
Everyone is valued at Venatorx and has a significant role in our success in improving health outcomes for patients with multi-drug-resistant bacterial infections and hard-to-treat viral infections.
Does it sound like a place you would like to work? Join our growing company!


Venatorx Pharmaceuticals is a private company focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant bacterial infections and hard-to-treat viral infections. The company has a world-class in-house research and development organization and is actively working on advancing antibiotic and antiviral therapies.

COM:VENATORX

Venatorx Pharmaceuticals

Filings Not Available